BCEL Atreca, Inc. - Class A

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.

$8.31
As of 06/23/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/20/2019
Outstanding shares:  30,178,367
Average volume:  588,757
Market cap:   $249,876,879
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    04965G109
ISIN:        US04965G1094
Sedol:      BJGSSC8

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   1.16
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%